Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

[Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma].

Ping LY, Zheng W, Wang XP, Xie Y, Lin NJ, Tu MF, Ying ZT, Zhang C, Liu WP, Deng LJ, Zhu J, Song YQ.

Zhonghua Yi Xue Za Zhi. 2012 Dec 11;92(46):3257-60. Chinese.

PMID:
23328509
3.

Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study.

Rosen O, Müller HJ, Gökbuget N, Langer W, Peter N, Schwartz S, Hähling D, Hartmann F, Ittel TH, Mück R, Rothmann F, Arnold R, Boos J, Hoelzer D.

Br J Haematol. 2003 Dec;123(5):836-41.

PMID:
14632774
4.

[A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy].

Yao G, Xie W, Zhou D, He D, He J, Shi J, Luo Y, Zheng W, Wei G, Lin M, Ye X, Cai Z, Huang H.

Zhonghua Nei Ke Za Zhi. 2015 Feb;54(2):111-7. Chinese.

PMID:
25907840
5.
6.

[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].

Cooperation Group of Phase II Clinical Trial of PEG-Asp..

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):29-33. Chinese.

PMID:
18512312
7.
8.

Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.

Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD.

Pediatr Blood Cancer. 2006 Feb;46(2):179-86.

PMID:
16007607
9.

[Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].

Yong W, Zheng W, Zhang Y.

Zhonghua Yi Xue Za Zhi. 2001 Jul 10;81(13):773-5. Chinese.

PMID:
11798962
10.

Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.

Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O.

Pediatr Blood Cancer. 2010 May;54(5):703-6. doi: 10.1002/pbc.22305.

PMID:
20063421
11.

Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.

Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, Zhang W, Ji X, Li P, Chen N, Zhao S, Wang F, Zou L.

Cancer. 2012 Jul 1;118(13):3294-301. doi: 10.1002/cncr.26629. Epub 2011 Dec 2.

12.

Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.

Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, Tura S, Mandelli F.

Eur J Haematol. 1992 Aug;49(2):63-6.

PMID:
1397242
13.

Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy.

Imamura T, Morimoto A, Kato R, Izumi M, Murakami A, Matuo S, Kiyosawa N, Kano G, Yoshioka H, Sugimoto T, Imashuku S.

Leuk Lymphoma. 2005 May;46(5):729-35.

PMID:
16019511
14.

L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.

Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J.

Int J Hematol. 2003 Aug;78(2):163-7.

PMID:
12953813
15.

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.

Kobayashi T, Tobinai K, Shimoyama M, Mikuni C, Konda S, Kozuru M, Araki K, Sai T, Fukuhara S, Matsumoto M, Aoki I, Deura K, Oyama A, Hotta T, Abe T, Toki H, Nagai M, Fukuda H, Niimi M, Yamaguchi N, Tajima K, Shirakawa S.

Jpn J Clin Oncol. 1999 Jul;29(7):340-8.

PMID:
10470659
16.

Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.

Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J.

Hematol Oncol. 2006 Mar;24(1):28-32.

PMID:
16323259
17.

Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.

Wiernik PH, Dutcher JP, Paietta E, Gucalp R, Markus S, Weinberg V, Azar C, Garl S, Benson L.

Leukemia. 1993 Aug;7(8):1236-41.

PMID:
8350624
18.

Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy.

Treepongkaruna S, Thongpak N, Pakakasama S, Pienvichit P, Sirachainan N, Hongeng S.

J Pediatr Hematol Oncol. 2009 Nov;31(11):812-5. doi: 10.1097/MPH.0b013e3181b87035.

PMID:
19801948
19.

Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.

Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, Lafon I, Cornillon J, Maakaroun A, Tizon A, Padrazzi B, Ifrah N, Gruel Y; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang)..

Haematologica. 2008 Oct;93(10):1488-94. doi: 10.3324/haematol.12948. Epub 2008 Aug 25.

20.

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.

Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB.

Leukemia. 1999 Mar;13(3):335-42.

PMID:
10086723

Supplemental Content

Support Center